GUCY1B1

Across TCGA pan-cancer cohorts, GUCY1B1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GUCY1B1 data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GUCY1B1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated GUCY1B1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and UCEC are the cancer types where GUCY1B1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.466	0.281	.002	48	view →
CCRCC	DFS	Tertile	III,IV	0.716	0.317	.010	9	view →
UCEC	DFS	Quartile	III,IV	0.294	1.000	.027	8	view →
LUAD	DFS	Median	All	0.768	0.467	.001	7	view →
LSCC	DFS	Quartile	II,III,IV	0.775	1.000	.027	6	view →
HNSC	DFS	Quartile	III,IV	0.966	0.734	.013	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GUCY1B1–PDAC (OS)

Open the PDAC breakdown →